Barclays raised the firm’s price target on HCA Healthcare (HCA) to $494 from $445 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q3 report.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $525 from $495 at UBS
- HCA Healthcare price target raised to $520 from $470 at Goldman Sachs
- HCA Healthcare price target raised to $425 from $400 at Morgan Stanley
- HCA Healthcare price target raised to $525 from $444 at Cantor Fitzgerald
- HCA Healthcare price target raised to $500 from $400 at Oppenheimer